Celldex Therapeutics (CLDX) EBIT Margin (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly EBIT Margin of 562900.0% for Q1 2026, down 55387281.0% year-over-year from N/an in Q1 2025, and down 681.51% quarter-over-quarter from 72027.27% in Q4 2025.
Powered by 
Analysis
Celldex Therapeutics (CLDX) EBIT Margin (2010 - 2026) Analysis & Trends
Celldex Therapeutics' EBIT Margin history runs 17 years deep, the most recent figure standing at 562900.0% for Q1 2026.
- In Q1 2026, EBIT Margin fell 55387281.0% year-over-year to 562900.0%; the TTM figure through Mar 2026 stood at 35688.45% (down 3281494.0% YoY), while the FY2025 annual figure was 18599.81%, down 1582092.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 562900.0%, down from 72027.27% in the prior quarter.
- The five-year high for EBIT Margin was 1152.92% in Q4 2023, with the low at 562900.0% in Q1 2026.
- The 5-year median for EBIT Margin is 7776.22% (2022), against an average of 46927.28%.
- The sharpest annual moves came in 2025 and 2026: EBIT Margin jumped 1700357 bps in 2025, then plunged 55387281 bps in 2026.
- Celldex Therapeutics' EBIT Margin stood at 1728.77% in 2022, then soared by 33 bps to 1152.92% in 2023, then slumped by 314 bps to 4768.26% in 2024, then slumped by 1411 bps to 72027.27% in 2025, then sank by 682 bps to 562900.0% in 2026.
- Business Quant data shows CLDX's EBIT Margin at 562900.0% in Q1 2026, 72027.27% in Q4 2025, and 8747.53% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Celldex Therapeutics | 3.10 Bn | 3.10 Bn | -2.57 Mn | -366,468.18% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -366,468.18% |
| Mar 31, 2026 | -562,900.00% |
| Dec 31, 2025 | -72,027.27% |
| Jun 30, 2025 | -8,747.53% |
| Mar 31, 2025 | -9,027.19% |
| Dec 31, 2024 | -4,768.26% |
| Sep 30, 2024 | -1,633.53% |
| Jun 30, 2024 | -1,854.16% |
| Mar 31, 2024 | -26,030.77% |
| Dec 31, 2023 | -1,152.92% |
| Sep 30, 2023 | -2,718.46% |
| Jun 30, 2023 | -12,389.93% |
| Mar 31, 2023 | -3,357.91% |
| Dec 31, 2022 | -1,728.77% |
| Sep 30, 2022 | -6,804.91% |
| Jun 30, 2022 | -22,328.83% |
| Mar 31, 2022 | -13,366.09% |
| Dec 31, 2021 | -6,089.82% |
| Sep 30, 2021 | -13,610.46% |
| Jun 30, 2021 | -386.21% |